NCT04495153Phase 2Active not recruiting

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Study sponsor: Candel Therapeutics, Inc. · CADL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12-31Actual
Enrollment · participants90Actual
Source updated2026-11-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview